Canada Spends Logo

Explorez notre analyse du budget 2026

Contribution: Industrial Research Assistance Program – Contributions to Firms

Alberta Research Chemicals Inc.

$50,400.00

Development of Novel Quinazoline-Based EGFR Inhibitors as Cancer Therapeutics

EF 2025-26 · 2025-07-01

Résumé
Firm would like to design and develop novel EGFR (epidermal growth factor receptor) inhibitor cancer therapeutic that improve selectivity to allow irreversible inhibition to overcome resistance mutations. EGFR plays a central role in cell proliferation and survival. Aberrant EGFR signaling is a driver mutation in many tumors, making it an ideal and validated target for cancer therapy. Despite many pharmaceutical companies actively advancing EGFR inhibitors, drug resistance and severe side effects remain unsolved challenges that need to be addressed.
Programme
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (lien de confiance élevée)
Emplacement
Edmonton|Edmonton, Alberta, Canada
Type de bénéficiaire
For-profit organization
Numéro d'entreprise
835357500
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions

Tel que publié

Agreement End Date
2026-03-31
Agreement Number
1032220
Agreement Start Date
2025-07-01
Agreement Title
Development of Novel Quinazoline-Based EGFR Inhibitors as Cancer Therapeutics
Agreement Title (French)
Développement de nouveaux inhibiteurs de l’EGFR à base de quinazoline pour le traitement du cancer
Agreement Type
Contribution
Agreement Value
$50,400.00
Amendment Number
0
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
Firm would like to design and develop novel EGFR (epidermal growth factor receptor) inhibitor cancer therapeutic that improve selectivity to allow irreversible inhibition to overcome resistance mutations. EGFR plays a central role in cell proliferation and survival. Aberrant EGFR signaling is a driver mutation in many tumors, making it an ideal and validated target for cancer therapy. Despite many pharmaceutical companies actively advancing EGFR inhibitors, drug resistance and severe side effects remain unsolved challenges that need to be addressed.
Description (French)
L’entreprise souhaite concevoir et développer de nouveaux inhibiteurs de l’EGFR (récepteur du facteur de croissance épidermique) pour le traitement du cancer, qui améliorent la sélectivité pour permettre une inhibition irréversible afin de surmonter les mutations de résistance. L’EGFR joue un rôle central dans la prolifération et la survie des cellules. La signalisation aberrante de l’EGFR est une mutation déterminante dans de nombreuses tumeurs, ce qui en fait une cible idéale et validée pour le traitement du cancer. Bien que de nombreuses sociétés pharmaceutiques développent activement des inhibiteurs de l’EGFR, la résistance aux médicaments et les effets secondaires graves restent des défis non résolus qui doivent être abordés.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Edmonton Mill Woods
Federal Riding (French)
Edmonton Mill Woods
Federal Riding Number
48017
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
835357500
Recipient City
Edmonton|Edmonton
Recipient Country
CA
Recipient Legal Name
Alberta Research Chemicals Inc.
Recipient Postal Code
T6E 5P8
Recipient Province or Territory
AB
Recipient Type
F
Reference Number
172-2025-2026-Q2-1032220